mTOR inhibition in management of advanced breast cancer

to related objects

Abstract: The mTOR pathway is becoming increasingly important in several cancers including breast cancer. This review will focus on the role of its inhibition in the management of advanced breast cancer.

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: mTOR inhibition in management of advanced breast cancer ; volume:33 ; number:02 ; year:2012 ; pages:89-94
Indian journal of medical & paediatric oncology ; 33, Heft 02 (2012), 89-94

Contributor: Nag, Shona

DOI: 10.4103/0971-5851.99737

URN: urn:nbn:de:101:1-2022060210104633518508

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Nag, Shona

Other Objects (12)

Nutritional and pharmacological modes of mTOR inhibition

Brain-restricted mTOR inhibition with binary pharmacology

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy

Clinical development of mTOR inhibitors in breast cancer

mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Hochschulschrift

Lysosomal activation and mTOR inhibition synergize to kill myeloid leukemia cells

HTLV-1 HBZ activates mTOR signaling pathway via inhibition of GADD34

Nutritional and pharmacological modes of mTOR inhibition

Brain-restricted mTOR inhibition with binary pharmacology

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy

Clinical development of mTOR inhibitors in breast cancer

mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Hochschulschrift

Lysosomal activation and mTOR inhibition synergize to kill myeloid leukemia cells

HTLV-1 HBZ activates mTOR signaling pathway via inhibition of GADD34

Nutritional and pharmacological modes of mTOR inhibition

Brain-restricted mTOR inhibition with binary pharmacology

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy

Clinical development of mTOR inhibitors in breast cancer

mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Hochschulschrift

Lysosomal activation and mTOR inhibition synergize to kill myeloid leukemia cells

HTLV-1 HBZ activates mTOR signaling pathway via inhibition of GADD34

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

mTOR inhibition in management of advanced breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Nutritional and pharmacological modes of mTOR inhibition

Brain-restricted mTOR inhibition with binary pharmacology

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy

Clinical development of mTOR inhibitors in breast cancer

mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Lysosomal activation and mTOR inhibition synergize to kill myeloid leukemia cells

HTLV-1 HBZ activates mTOR signaling pathway via inhibition of GADD34

Nutritional and pharmacological modes of mTOR inhibition

Brain-restricted mTOR inhibition with binary pharmacology

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy

Clinical development of mTOR inhibitors in breast cancer

mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Lysosomal activation and mTOR inhibition synergize to kill myeloid leukemia cells

HTLV-1 HBZ activates mTOR signaling pathway via inhibition of GADD34

Nutritional and pharmacological modes of mTOR inhibition

Brain-restricted mTOR inhibition with binary pharmacology

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy

Clinical development of mTOR inhibitors in breast cancer

mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Lysosomal activation and mTOR inhibition synergize to kill myeloid leukemia cells

HTLV-1 HBZ activates mTOR signaling pathway via inhibition of GADD34

Related objects

Reset password